Biomedical Engineering Reference
In-Depth Information
•
Long-term drug elution and tolerance by the vessel wall
•
An easy procedure with a short completion time
•
Low cost
All of these requirements are not fulfilled by the available DES. Suggestions for
further improvements are made in the section on future prospects at the end of this
chapter.
Companies Developing Drug-Eluting Stents
Various companies involved in drug-eluting stents are shown in Table
9.3
.
Table 9.3
Companies involved in drug-eluting stents
Company
Product
Status
Launched in Europe
in 2003
Abbott vascular
devices
Dexamet stent (a drug-eluting stent)
elutes dexamethasone into the tissue
at the time inflammation and reduces
restenosis
ZoMaxx drug-eluting coronary
stent (a unique formulation of
phosphorylcholine polymer coating)
for the slow, controlled release
of ABT-578 − a cytostatic that blocks
the function of the cell cycle
regulatory protein mTOR
Phase III development
discontinued
to focus on
Xience V
XIENCE V system uses the drug
everolimus and MULTI-LINK
VISION
®
coronary stent platform
Launched/Europe
Investigational/US
Angiotech
pharmaceuticals
Polymeric formulations to deliver
paclitaxel as a stent coating for
restenosis
Phase III
Biosensors International
Absorbable DES using Biolimus A9
Preclinical
Boston Scientific
TAXUS Liberté system: Paclitaxel
coated stents, which slow microtubule
degradation after cell division
Phase III US marketed
in other countries
Conor Medsystems Inc
CoStar
™
(CObalt chromium STent
with Antiproliferative for
Restenosis) cobalt chromium
paclitaxel-eluting stent
Phase II started 2005
Cordis corporation
CYPHER
®
Sirolimus-eluting
Coronary Stent: releases sirolismus,
an antirejection drug that limits
the overgrowth of normal cells
while the artery heals
Marketed
Endovasc Ltd
PROStent, comprised of a polymer
and PGE-1, slowly releases PGE-1
to prevent restenosis
Completed preclinical
(continued)
Search WWH ::
Custom Search